Molecule Structure

Scientific Name

Ceritinib

Description of the Drug

Ceritinib is an antineoplastic kinase inhibitor used to treat anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) in patients with inadequate clinical response or intolerance to crizotinib.

Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB09063

Brand Name(s)

Zykadia

Company Owner(s)

Novartis Pharmaceuticals Corp

Mechanism(s) Of Action

Target Name Target Type Action Type Target ChEMBL ID
EML4-ALK CHIMERIC PROTEIN INHIBITOR CHEMBL3883330
ALK tyrosine kinase receptor SINGLE PROTEIN INHIBITOR CHEMBL4247
NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor) CHIMERIC PROTEIN INHIBITOR CHEMBL2111387

Unichem Links

SureChEMBL SCHEMBL1014329
Human Metabolome Database HMDB0249821
DrugBank DB09063
PubChem: Thomson Pharma 136885241
PubChem 57379345
LINCS LSM-36374
Nikkaji J3.252.917H
PDBe 4MK
BindingDB 50436850
EPA CompTox Dashboard DTXSID10725373
DrugCentral 4866
Brenda 255717
ChemicalBook CB82652832
Guide to Pharmacology 7397
rxnorm ZYKADIA CERITINIB
ChEBI 78432
ZINC ZINC000096272772